MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326690 | Name: Ambrisentan
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ambrisentan, also known as BSF-208075 and LU-208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind, multicenter trials (ARIES-1 and ARIES-2). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency, and designated an orphan drug, for the treatment of pulmonary hypertension.

Chemical Structure

Ambrisentan
Ambrisentan
CAS#177036-94-1

Theoretical Analysis

MedKoo Cat#: 326690

Name: Ambrisentan

CAS#: 177036-94-1

Chemical Formula: C22H22N2O4

Exact Mass: 378.1580

Molecular Weight: 378.43

Elemental Analysis: C, 69.83; H, 5.86; N, 7.40; O, 16.91

Price and Availability

Size Price Availability Quantity
500mg USD 110.00 Ready to ship
1g USD 190.00 Ready to ship
2g USD 350.00 Ready to ship
5g USD 750.00 Ready to ship
10g USD 1,350.00 Ready to ship
20g USD 2,350.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BSF-208075; BSF208075; BSF 208075; LU-208075; LU208075; LU 208075; Ambrisentan. trade name Letairis; Volibris; pulmonext.
IUPAC/Chemical Name
(S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
InChi Key
OUJTZYPIHDYQMC-LJQANCHMSA-N
InChi Code
InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
SMILES Code
O=C(O)[C@@H](OC1=NC(C)=CC(C)=N1)C(C2=CC=CC=C2)(OC)C3=CC=CC=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Ambrisentan is a selective ET type A receptor (ETAR) antagonist.
In vitro activity:
Ambrisentan reduced the migration capacity of COLO-357 pancreatic carcinoma cells in the presence or absence of PAR2 induction (Fig. 1b). In concordance with these data, Ambrisentan also blocked the migration of other tumor cells such as OvCar3 ovarian carcinoma (Supplementary Fig. S1a) and HL-60 promyelocytic leukemia cell line (Supplementary Fig. S1b). This study also analyzed the effect of Ambrisentan on the functional capacity of MDA-MB231 breast adenocarcinoma, a cell line shown to be positive for ETAR expression (Fig. 2a). The findings demonstrate that treatment with up to 100 µM Ambrisentan had no effect on viability of cancer cells (Fig. 2b). However, the migration and invasion capacities of MDA-MB-231 cells, which are known to contribute to the tumorigenicity of these triple-negative breast cancer cells were significantly inhibited after a 24 h-exposure to Ambrisentan in a dose-dependent manner (Fig. 2c, d). Reference: Sci Rep. 2020; 10: 15931. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522204/
In vivo activity:
Results from the current study reveal that oral administration of low dose ambrisentan reduced the RV pressure and RV hypertrophy at weeks 2 and 4 after administration. Recovery in the BW, and decrease in the medial wall thickness of pulmonary arteriole and the number of intra-acinar arteries were observed at week 4. Protein expression levels of ET-1 and eNOS were recovered in the lung tissues of MCT-induced PAH rat model at weeks 2 and 4, whereas protein expression of ERA was decreased at week 4. Reference: Korean Circ J. 2019 Sep; 49(9): 866–876. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713827/
Solvent mg/mL mM
Solubility
DMSO 87.5 231.22
Ethanol 6.6 17.36
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 378.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Masi I, Caprara V, Spadaro F, Chellini L, Sestito R, Zancla A, Rainer A, Bagnato A, Rosanò L. Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. Cell Rep. 2021 Mar 2;34(9):108800. doi: 10.1016/j.celrep.2021.108800. PMID: 33657382. 2. Kappes L, Amer RL, Sommerlatte S, Bashir G, Plattfaut C, Gieseler F, Gemoll T, Busch H, Altahrawi A, Al-Sbiei A, Haneefa SM, Arafat K, Schimke LF, Khawanky NE, Schulze-Forster K, Heidecke H, Kerstein-Staehle A, Marschner G, Pitann S, Ochs HD, Mueller A, Attoub S, Fernandez-Cabezudo MJ, Riemekasten G, Al-Ramadi BK, Cabral-Marques O. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Sci Rep. 2020 Sep 28;10(1):15931. doi: 10.1038/s41598-020-72960-1. PMID: 32985601; PMCID: PMC7522204. 3. Lee H, Yeom A, Kim KC, Hong YM. Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model. Korean Circ J. 2019 Sep;49(9):866-876. doi: 10.4070/kcj.2019.0006. Epub 2019 Apr 25. PMID: 31165592; PMCID: PMC6713827. 4. Zhang L, Zou Y, Song SH, Wang ZX, Ding GS, Ma J, Ni ZJ, Fu H, Shi XM, Gao XG, Han QC, Guo WY, Fu ZR. Ambrisentan improves the outcome of rats with liver transplantation partially through reducing nephrotoxicity. Eur Rev Med Pharmacol Sci. 2014;18(17):2575-83. PMID: 25268107.
In vitro protocol:
1. Masi I, Caprara V, Spadaro F, Chellini L, Sestito R, Zancla A, Rainer A, Bagnato A, Rosanò L. Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. Cell Rep. 2021 Mar 2;34(9):108800. doi: 10.1016/j.celrep.2021.108800. PMID: 33657382. 2. Kappes L, Amer RL, Sommerlatte S, Bashir G, Plattfaut C, Gieseler F, Gemoll T, Busch H, Altahrawi A, Al-Sbiei A, Haneefa SM, Arafat K, Schimke LF, Khawanky NE, Schulze-Forster K, Heidecke H, Kerstein-Staehle A, Marschner G, Pitann S, Ochs HD, Mueller A, Attoub S, Fernandez-Cabezudo MJ, Riemekasten G, Al-Ramadi BK, Cabral-Marques O. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Sci Rep. 2020 Sep 28;10(1):15931. doi: 10.1038/s41598-020-72960-1. PMID: 32985601; PMCID: PMC7522204.
In vivo protocol:
1. Lee H, Yeom A, Kim KC, Hong YM. Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model. Korean Circ J. 2019 Sep;49(9):866-876. doi: 10.4070/kcj.2019.0006. Epub 2019 Apr 25. PMID: 31165592; PMCID: PMC6713827. 2. Zhang L, Zou Y, Song SH, Wang ZX, Ding GS, Ma J, Ni ZJ, Fu H, Shi XM, Gao XG, Han QC, Guo WY, Fu ZR. Ambrisentan improves the outcome of rats with liver transplantation partially through reducing nephrotoxicity. Eur Rev Med Pharmacol Sci. 2014;18(17):2575-83. PMID: 25268107.
1: Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M, Waterhouse B, Langley J, Galié N. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. J Heart Lung Transplant. 2016 May 6. pii: S1053-2498(16)30117-6. doi: 10.1016/j.healun.2016.04.013. [Epub ahead of print] PubMed PMID: 27282418. 2: Cedars AM, Saef J, Peterson LR, Coggan AR, Novak EL, Kemp D, Ludbrook PA. Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure. Am J Cardiol. 2016 May 1;117(9):1524-32. doi: 10.1016/j.amjcard.2016.02.024. Epub 2016 Feb 23. PubMed PMID: 27063478. 3: Takeuchi T, Sakao S, Kato F, Naito A, Jujo T, Yasuda T, Tanabe N, Tatsumi K. Pulmonary haemodynamics are correlated with intimal lesions in a rat model of severe PAH: attenuation of pulmonary vascular remodelling with ambrisentan. Histol Histopathol. 2016 Apr 6:11764. [Epub ahead of print] PubMed PMID: 27048555. 4: Hakamata A, Odagiri K, Miyakawa S, Irisawa H, Takeuchi K, Inui N, Tanaka S, Uchida S, Watanabe H. Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. Clin Transl Sci. 2016 Feb;9(1):29-35. doi: 10.1111/cts.12382. Epub 2016 Jan 12. PubMed PMID: 26756977. 5: Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension. Med Lett Drugs Ther. 2016 Jan 4;58(1485):2-4. PubMed PMID: 26714240. 6: Enderle Y, Meid AD, Friedrich J, Grünig E, Wilkens H, Haefeli WE, Burhenne J. Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. Anal Chem. 2015 Dec 15;87(24):12112-20. doi: 10.1021/acs.analchem.5b03077. Epub 2015 Dec 3. PubMed PMID: 26583764. 7: Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC. PubMed PMID: 26360334; PubMed Central PMCID: PMC4642204. 8: Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. PubMed PMID: 26308684. 9: Patel JK, Patel NK. Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form. Sci Pharm. 2014 May 22;82(4):749-63. doi: 10.3797/scipharm.1403-22. eCollection 2014 Dec. PubMed PMID: 26279975; PubMed Central PMCID: PMC4500576. 10: Peacock AJ, Zamboni W, Vizza CD. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. Curr Med Res Opin. 2015;31(9):1793-807. doi: 10.1185/03007995.2015.1074890. Epub 2015 Aug 27. Review. PubMed PMID: 26196225. 11: Muraoka H, Imamura T, Hatano M, Maki H, Yao A, Kinugawa K, Komuro I. Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect. Int Heart J. 2015;56(4):471-3. doi: 10.1536/ihj.15-007. Epub 2015 Jun 18. PubMed PMID: 26084462. 12: Bose N, Bena J, Chatterjee S. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther. 2015 Mar 5;17:44. doi: 10.1186/s13075-015-0558-9. PubMed PMID: 25876611; PubMed Central PMCID: PMC4384235. 13: Li XQ, Li YJ, Wang Y. Ambrisentan May Improve Exercise Tolerance and Cardiac Function in Patients With Pulmonary Hypertension. Clin Ther. 2015 Jun 1;37(6):1270-9. doi: 10.1016/j.clinthera.2015.03.011. Epub 2015 Apr 7. Review. PubMed PMID: 25862136. 14: Yamashita Y, Tsujino I, Sato T, Yamada A, Watanabe T, Ohira H, Nishimura M. Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol. 2014 Nov 27;6(11):825-9. doi: 10.4254/wjh.v6.i11.825. PubMed PMID: 25429321; PubMed Central PMCID: PMC4243157. 15: Markert C, Kastner IM, Hellwig R, Kalafut P, Schweizer Y, Hoffmann MM, Burhenne J, Weiss J, Mikus G, Haefeli WE. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin Pharmacol Toxicol. 2015 May;116(5):423-8. doi: 10.1111/bcpt.12332. Epub 2014 Nov 8. PubMed PMID: 25286744. 16: Zhang L, Zou Y, Song SH, Wang ZX, Ding GS, Ma J, Ni ZJ, Fu H, Shi XM, Gao XG, Han QC, Guo WY, Fu ZR. Ambrisentan improves the outcome of rats with liver transplantation partially through reducing nephrotoxicity. Eur Rev Med Pharmacol Sci. 2014;18(17):2575-83. PubMed PMID: 25268107. 17: Markert C, Wirsching T, Hellwig R, Burhenne J, Weiss J, Riedel KD, Mikus G, Haefeli WE. Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. Int J Clin Pharmacol Ther. 2014 Nov;52(11):957-64. doi: 10.5414/CP202164. PubMed PMID: 25207548. 18: Wen L, Jiang X, An P, He J, Zheng L, Liu Q, Peng F, Xu X, Jing Z. [Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Jun;42(6):469-73. Chinese. PubMed PMID: 25164219. 19: Chung L, Ball K, Yaqub A, Lingala B, Fiorentino D. Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol. 2014 Aug;71(2):400-1. doi: 10.1016/j.jaad.2014.04.028. PubMed PMID: 25037794; PubMed Central PMCID: PMC4356009. 20: Condliffe R, Elliot CA, Hurdman J, Sabroe I, Billings C, Kiely DG, Hamilton N. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis. 2014 Apr 30;8(3):71-77. [Epub ahead of print] PubMed PMID: 24787237.